{"id":"NCT00512135","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines","officialTitle":"A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06-18","primaryCompletion":"2009-12-28","completion":"2009-12-28","firstPosted":"2007-08-07","resultsPosted":"2021-04-02","lastUpdate":"2021-04-02"},"enrollment":801,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Lines"],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (Xeomin) (20 units)","otherNames":["IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins (20 units)"]}],"arms":[{"label":"IncobotulinumtoxinA (Xeomin) (20 units)","type":"EXPERIMENTAL"}],"summary":"The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.","primaryOutcome":{"measure":"Incidence of Adverse Events (AEs)","timeFrame":"Baseline up to Month 30","effectByArm":[{"arm":"IncobotulinumtoxinA 20 U","deltaMin":374,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["United States","Canada","Germany"]},"refs":{"pmids":["23190342"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":796},"commonTop":["Nasopharyngitis","Headache"]}}